Scroll Up Top
Print icon
Print
Overview

Overview

1
The Fund

The Fund invests worldwide in companies principally engaged in the discovery, development, production or distribution of products (or services) related to scientific advances in health care, including biotechnology, pharmaceuticals, diagnostics, managed health care, and medical equipment and supplies.

2
The Approach

The portfolio managers seek to purchase stocks that are reasonably priced in relation to their fundamental value and that the portfolio managers believe will grow in value over time regardless of short-term market fluctuations. The stock selection process is based on numerous factors, including the potential to increase market share (for larger companies), and the potential of research and development projects (for smaller companies). The team is based in Boston and London.

3
The Features

Growth in the health care sector is led by aging demographics, innovation and rising global incomes. As the global population ages and becomes wealthier, we believe health care spending is likely to continue to rise. Innovation drives growth in the sector, as increased scientific understanding leads to new breakthroughs.

Fund Facts

Asset Class Global Equity
Morningstar Category Health
Share Class Inception Date 07/26/1985
Performance Inception 07/26/1985
Investment Objective Long-term capital growth
Net Asset Value ($):
as of 08/05/2025
12.50
Fund Assets ($MM):
as of 06/30/2025
860.66
Share Class Assets ($MM):
as of 08/05/2025
572.89
Distribution Frequency Annually
Benchmark MSCI World Health Care Index

Pricing & Performance

Performance data quoted represents past performance, which is no guarantee of future results, and current performance may be lower or higher than the figures shown. For the most recent month-end performance figures, please select the "month" timeframe or call 1-800-836-2414. Investment returns and principal value will fluctuate and fund shares, when redeemed, may be worth more or less than their original cost. For additional important information, please click here.

Fees & Expenses

Gross Expense Ratio (%) 1.20
Net Expense Ratio (%) 1.17
Maximum Sales Charge (%) 5.25
Minimum Initial Investment ($) 1,000

Growth of Investment

As of 07/31/2025 (updated monthly upon availability)
download image

Download

Created with Highcharts 11.0.0Cash Value ($)Performance of $10,000 investedETHSX07/31/201501/31/201807/31/202001/31/202307/31/20255k7.5k10k12.5k15k17.5k20k22.5k

Past performance is not indicative of future results.

Average Annual Total Returns

As of 06/30/2025

Created with Highcharts 11.0.0%-15-10-50510
ETHSX Shares
ETHSX Shares with Max. 5.25% Sales Charge
MSCI World Health Care Index
1 Month3 MonthsYTD1 YR3 YR5 YR10 YR
ETHSX Shares 1.03 -4.33 -1.00 -6.92 3.19 5.91 5.63
ETHSX Shares with Max. 5.25% Sales Charge -4.26 -9.34 -6.22 -11.82 1.36 4.77 5.06
MSCI World Health Care Index 1.45 -4.09 0.80 -5.60 3.71 6.05 6.40

Past performance is not indicative of future results. The Portfolio's calendar year returns do not include the deduction of any applicable sales charges.

Distributions

Ex-DateNet Investment Income ($ per share)Long-Term Capital Gains ($ per share)Short-Term Capital Gains ($ per share)Total Capital Gains ($ per share)
12/05/2024 0.024300 0.598700 0.000000 0.598700
12/07/2023 0.016600 0.307700 0.000000 0.307700

Morningstar Rankings

As of 06/30/2025

PercentileRank/Total in Category
1 Year6298/176
3 Year56106/164
5 Year2635/150
10 Year4143/118

Rankings are based on total returns, are historical and do not guarantee future results. For additional Morningstar information, refer to the disclosures below.

Composition

Composition

As of 06/30/2025

Created with Highcharts 11.0.0
Fund
North America
76.88
Europe
20.53
Asia/Pacific
2.59

May not sum to 100% due to the exclusion of other assets and liabilities.

Holdings

As of 06/30/2025

Download iconDownload Full Holdings

Top 10 Holdings (% of Total Net Assets)
Fund
Eli Lilly & Co 10.52
AbbVie Inc 5.67
AstraZeneca PLC 5.16
Abbott Laboratories 5.10
Roche Holding AG 4.84
Novo Nordisk A/S 4.56
Johnson & Johnson 3.48
Intuitive Surgical Inc 3.48
Zoetis Inc 3.34
Boston Scientific Corp 3.04

Portfolio Characteristics

As of 06/30/2025

Fund
Number of Holdings 47

Portfolio turnover is sourced from the fund's current prospectus. View current prospectus for the as of date.

Portfolio Managers
professional image
Jason Kritzer, CFA
Managing Director
26
professional image
Samantha Pandolfi, CFA
Managing Director
25

Team members may be subject to change at any time without notice.

This material is a general communication, which is not impartial and all information provided has been prepared solely for informational and educational purposes and does not constitute an offer or a recommendation to buy or sell any particular security or to adopt any specific investment strategy. The information herein has not been based on a consideration of any individual investor circumstances and is not investment advice, nor should it be construed in any way as tax, accounting, legal or regulatory advice. To that end, investors should seek independent legal and financial advice, including advice as to tax consequences, before making any investment decision.

Where the net expense ratio is lower than the gross expense ratio, certain fees have been waived and/or expenses reimbursed. These waivers and/or reimbursements will continue for at least one year from the date of the applicable fund’s current prospectus (unless otherwise noted in the applicable prospectus) or until such time as the fund's Board of Directors acts to discontinue all or a portion of such waivers and/or reimbursements. Absent such waivers and/or reimbursements, returns would have been lower. Expenses are based on the fund's current prospectus. The minimum initial investment is $1,000,000 for Class I shares.

Class R6 shares, are being offered only to eligible investors who must meet a minimum initial investment of $5,000,000 or be a defined contribution, defined benefit or other employer sponsored employee benefit plan, whether or not qualified under the Internal Revenue Code of 1986, as amended (the "Code"), in each case subject to the discretion of the Portfolio's investment advisor.

Growth of Investment illustration is based on an initial investment of $10,000 made since fund inception, assumes reinvestment of dividends and capital gains and application of fees, but does not include sales charges. Performance would have been lower if sales charges had been included. Results are hypothetical.

Past performance is not indicative of future results. Subject to change daily. Fund information is provided for informational purposes only and should not be deemed as a recommendation to buy or sell any security or securities in the sectors and countries that may be presented.

Index data displayed under characteristics and allocations are calculated using MSIM and/or other third-party methodologies and may differ from data published by the vendor.

DEFINITIONS:

Number of holdings provided are a typical range, not a maximum number. The portfolio may exceed this from time to time due to market conditions and outstanding trades.

INDEX INFORMATION:

The MSCI World Health Care Index is a capitalization weighted index that monitors the performance of health care stocks from developed market countries in North America, Europe and the Asia/Pacific Region. The index includes reinvestment of dividends, net of foreign withholding taxes.

MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder. Unless otherwise stated, index returns do not reflect the effect of any applicable sales charges, commissions, expenses, taxes or leverage, as applicable. It is not possible to invest directly in an index. Historical performance of the index illustrates market trends and does not represent the past or future performance of the fund.

RISK CONSIDERATIONS:

The value of investments held by the Fund may increase or decrease in response to economic, and financial events (whether real, expected or perceived) in the U.S. and global markets. The value of equity securities is sensitive to stock market volatility. Because the Fund investments may be concentrated in a particular industry, the Fund share value may fluctuate more than that of a less concentrated fund. Investments in foreign instruments or currencies can involve greater risk and volatility than U.S. investments because of adverse market, economic, political, regulatory, geopolitical, currency exchange rates or other conditions. Smaller companies are generally subject to greater price fluctuations, limited liquidity, higher transaction costs and higher investment risk than larger, more established companies. The Fund is exposed to liquidity risk when trading volume, lack of a market maker or trading partner, large position size, market conditions, or legal restrictions impair its ability to sell particular investments or to sell them at advantageous market prices. The impact of the coronavirus on global markets could last for an extended period and could adversely affect the Fund’s performance. No fund is a complete investment program and you may lose money investing in a fund. The Fund may engage in other investment practices that may involve additional risks and you should review the Fund prospectus for a complete description.

Morningstar
Rankings: The percentile rankings are based on the average annual total returns for the periods stated and do not include any sales charges, but do include reinvestment of dividends and capital gains and Rule 12b-1 fees. The highest (or most favorable) percentile rank is 1 and the lowest (or least favorable) percentile rank is 100. The top-performing fund in a category will always receive a rank of 1.

Ratings: The Morningstar Rating™ for funds, or "star rating", is calculated for managed products (including mutual funds, variable annuity and variable life subaccounts, exchange-traded funds, closed-end funds, and separate accounts) with at least a three-year history. Exchange-traded funds and openended mutual funds are considered a single population for comparative purposes. It is calculated based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product's monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star. The Overall Morningstar Rating for a managed product is derived from a weighted average of the performance figures associated with its three-, five-, and 10-year (if applicable) Morningstar Rating metrics. The weights are: 100% three-year rating for 36-59 months of total returns, 60% five-year rating/40% three-year rating for 60-119 months of total returns, and 50% 10-year rating/30% five-year rating/20% three-year rating for 120 or more months of total returns. While the 10-year overall star rating formula seems to give the most weight to the 10-year period, the most recent three-year period actually has the greatest impact because it is included in all three rating periods. Ratings do not take into account sales loads.

© 2025 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results. Morningstar information is based on quarter-end data. Please visit eatonvance.com for the latest month-end Morningstar information.

Please consider the investment objective, risks, charges and expenses of the fund carefully before investing. The prospectus contains this and other information about the fund. To obtain a prospectus (which includes the applicable fund's current fees and expenses, if different from those in effect as of the date of this fact sheet), download one here or contact your financial professional. Please read the prospectus carefully before investing.

Eaton Vance is part of Morgan Stanley Investment Management. Morgan Stanley Investment Management is the asset management division of Morgan Stanley.